Recombinant zoster vaccine ( DrugBank: - )


2 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica1
49Systemic lupus erythematosus1

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,340 Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05596526
(ClinicalTrials.gov)
November 1, 202224/10/2022Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis PatientsImmunogenicity of the Recombinant Zoster Vaccine (Shingrix ®) in Multiple Sclerosis Patients Treated With Anti-CD20 Antibodies Compared to Controls- a Phase IV Monocentric StudyShingles;ZosterBiological: recombinant zoster vaccineProf Patrice LaliveNULLNot yet recruiting18 Years60 YearsAll100Phase 4Switzerland

49. Systemic lupus erythematosus


Clinical trials : 993 Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04516408
(ClinicalTrials.gov)
April 20, 202113/8/2020Recombinant Zoster Vaccine in Stable SLE PatientsEfficacy and Safety of Recombinant Zoster Vaccine in Stable SLE Patients(Vtrial)Herpes Zoster;Recombinant Zoster Vaccine;Systemic Lupus ErythematosusBiological: Recombinant zoster vaccine;Biological: PlaceboRenJi HospitalNULLRecruiting50 YearsN/AAll464N/AChina